Through leukapheresis the blood and cells are separated into its constituent parts using centrifugation. During leukapheresis, the cells are collected in a “Leukopak”.
During the leukapheresis procedure, white blood cells are enriched and extracted according to need. Leukapheresis is carried out using machines (apheresis devices). We are using the Spectra Optia® Apheresis System CMNC collection protocol in ACD-A anticoagulant.
Leukopaks are therefore the result of leukapheresis. Through this procedure collection and enrichment of white blood cells from multiple volumes of healthy donor peripheral blood is achieved by a simultaneous return of non-targeted blood cells to circulation. This procedure results in large yields of single-donor mononuclear cells (MNCs), limiting the impact of donor-to-donor variability. Cyto-care offers leukopaks fresh and cryopreserved, thus allowing for scalability and reproducibility of experiments and in different formats:
- Mononuclear Cells (PBMCs)
- Subpopulations: T Cells, B Cells, NK Cells and Monocytes
Cryopreserved leukopaks are cryopreserved on site immediately following collection and are prepared cells for long-term storage in liquid nitrogen vapor phase and thaw for use. Storage in liquid phase nitrogen is NOT recommended. Short-term storage of cells (less than 2 weeks) at -80 °C is acceptable but should be minimized to ensure maximum stability. Once thawed, samples must be used immediately.
Testing: Donors are tested for HBV, HCV, HIV, HTLV, WNV and Syphilis. We ensure that fresh donor material is available to customers. Since 2006, our key competence has been the collection and purification of human blood cells by leukapheresis for clinical trials and research purposes. We also offer medical and scientific consulting in the area of cell therapy to medical specialists, research organizations and pharmaceutical companies.
We perform our leukapheresis with single-use kits.